Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 104 Neoplasms 13 Neoplasm Metastasis 8 Sarcoma 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Melanoma 5 Leukemia, Myeloid, Acute 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Liposarcoma 4 Multiple Myeloma 3 Head and Neck Neoplasms 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Diseases 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Inflammation 2 Estrogen Receptor-positive Breast Cancer 2 Esophageal Squamous Cell Carcinoma 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × palbociclib × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡